A 2-week, Phase 1, Placebo-Controlled, Parallel Group Trial To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Multiple Oral Doses Of PF-04991532 Given As Monotherapy To Adult Patients With Type 2 Diabetes Mellitus.
Phase of Trial: Phase I
Latest Information Update: 29 Oct 2013
At a glance
- Drugs PF 4991532 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 25 Jun 2013 Results presented at the 73rd Annual Scientific Sessions of the American Diabetes Association.
- 27 Jun 2012 Actual patient number 82 added as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History